Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar
By Katherine Hamilton
Teva Pharmaceuticals received approval from the Food and Drug Administration for its drug Degevma as a biosimilar to the bone-cancer treatment Xgeva.
Degevma is indicated to prevent bone complications in adults with advanced cancer that has spread to the bone. It is also indicated to treat people with giant cell tumor of bone and hypercalcemia of malignancy, which is a blood condition caused by cancer.
The FDA's approval was based on data demonstrating similar efficacy and safety to Xgeva, which is also used to prevent bone problems in people with cancer.
Teva said the approval could bring about lower healthcare costs for patients. The company also received approval from the FDA in March for its drug Ponlimsi as a biosimilar.
Teva plans to launch both Degevma and Ponlimsi in the U.S. in the coming months, aligning with its broader biosimilar commercialization strategy. Degevma is currently approved in the European Union.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 28, 2026 17:11 ET (21:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States